Skip to main content
峆一药业 logo

峆一药业 — Investor Relations & Filings

Ticker · 920478 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 363 across all filing types
Latest filing 2024-10-21 Proxy Solicitation & In…
Country CN China
Listing Beijing Stock Exchange 920478

About 峆一药业

http://www.heryipharma.com/

Anhui Heyi Pharmaceutical Co., Ltd. specializes in the research, development, production, and sales of pharmaceutical intermediates and active pharmaceutical ingredients (APIs). The company focuses on providing high-quality chemical products for various therapeutic areas, including cardiovascular, central nervous system, and anti-infective treatments. With a strong emphasis on technological innovation and quality control, it operates advanced manufacturing facilities that adhere to international standards. Its product portfolio includes key intermediates for widely used medications, supporting both domestic and global pharmaceutical supply chains. The company leverages its expertise in complex chemical synthesis to offer customized solutions and reliable supply to its partners in the life sciences sector.

Recent filings

Filing Released Lang Actions
关于独立董事公开征集表决权公告
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a public announcement by independent directors soliciting proxy voting rights from shareholders for a specific upcoming extraordinary general meeting scheduled for November 7, 2024. It details the agenda items related to a 2024 equity incentive plan and the procedures for shareholders to authorize voting rights to the independent directors. The document includes instructions on submitting proxy forms and legal compliance statements. There are no financial statements, earnings data, or management discussion of financial results. The document is not a report but an announcement related to proxy solicitation for a shareholder meeting. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI). The document length is under 5,000 characters, but it contains detailed proxy solicitation content rather than a mere announcement of a report publication, so it is not RPA or RNS.
2024-10-21 Chinese
关于对拟认定核心员工进行公示并征求意见的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Anhui Xuyi Pharmaceutical Co., Ltd. regarding the nomination and public disclosure of core employees, including a list of nominated individuals and a solicitation for employee feedback during a specified public notice period. It references a board meeting resolution and the process for employee objections and subsequent supervisory board and shareholder meeting review. There is no financial data, no mention of financial results, no regulatory filings related to financial performance, no voting results, no executive compensation details, and no merger or capital structure changes. The document is a formal announcement related to internal company personnel matters, specifically the nomination of core employees, which does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is not a report publication announcement or a certification. The closest fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements that do not fit other categories.
2024-10-21 Chinese
上海德禾翰通律师事务所关于安徽峆一药业股份有限公司2024年股权激励计划（草案）的法律意见书
Regulatory Filings Classification · 58% confidence The document is a standalone legal opinion letter (“法律意见书”) issued by a law firm concerning Anhui Yi One Pharmaceutical Co.’s proposed 2024 share incentive plan. It does not constitute an annual or interim financial report, earnings release, proxy statement or statutory meeting materials, nor a transcript or capital-raising announcement. Instead, it is a regulatory compliance/legal advisory submission. Under FinancialReports definitions, such regulatory or compliance filings that do not fit other categories fall under “Regulatory Filings” (RNS).
2024-10-21 Chinese
2024年股权激励计划（草案）
Regulatory Filings Classification · 95% confidence The document is titled "安徽峆一药业股份有限公司 2024 年股权激励计划（草案）" which translates to "Anhui Xuyi Pharmaceutical Co., Ltd. 2024 Equity Incentive Plan (Draft)". It is a detailed draft plan for a stock-based incentive program for employees and management, including directors and senior executives. The document includes legal references, detailed terms of the incentive plan, eligibility criteria, stock grant details, vesting and lock-up periods, performance conditions, and governance procedures related to the equity incentive plan. It is not a financial report, earnings release, or regulatory filing about financial results or corporate governance changes. It is also not an announcement or summary but a full draft plan document. This type of document fits best under the category of Regulatory Filings (RNS) because it is a regulatory disclosure of a corporate equity incentive plan, which does not fall under other more specific categories such as Management Information, Capital Update, or Remuneration Information. The document is substantive and detailed but does not constitute an annual report, audit report, or earnings release. Therefore, the best classification is Regulatory Filings (RNS).
2024-10-21 Chinese
独立董事专门会议关于第四届董事会第二十次会议相关事项的审查意见的公告
Board/Management Information Classification · 95% confidence The document is an announcement from the independent directors of Anhui Xuyi Pharmaceutical Co., Ltd. regarding their review opinions on several board meeting agenda items related to the company's 2024 equity incentive plan. It includes detailed opinions on the legality, compliance, and procedural correctness of the equity incentive plan, core employee nominations, and related agreements. The document is not a full financial report, earnings release, or regulatory certification. It is a formal announcement of the independent directors' review and approval opinions on board matters, which fits the category of Board/Management Information (MANG). The document length is 1965 characters, which is relatively short but contains substantive content about board decisions rather than just an announcement of a report publication or voting results. Therefore, the best classification is MANG with high confidence.
2024-10-21 Chinese
第四届监事会第十九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Anhui Xuyi Pharmaceutical Co., Ltd. It details the meeting date, attendance, and the approval of several proposals related to the company's 2024 equity incentive plan and related matters. The document is a formal announcement of meeting decisions and voting results, not a full report or detailed financial statement. It does not contain financial data or detailed management discussion but rather the outcomes of board-level decisions. The document length is 2433 characters, which is relatively short and consistent with a meeting resolution announcement. Therefore, it fits best under the category of Board/Management Information (MANG), which covers announcements of changes or decisions by company boards or senior management bodies.
2024-10-21 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.